Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " ?g. }

• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.
• _3 value "Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment. To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxon's signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis). " provenance.